IV | Jotup

REVIV, the Global Leader in Personalized and Precision Nutrition, Launches REVIV 2.0, the Next Chapter in Brand History Powered by Over 10 Years of Experience and 2M+ IV Therapies Delivered

Retrieved on:

Thursday, October 12, 2023

Health, Nutrient, Safety, IV, Growth, Marketing, Mineral, Vitamin, Electrolyte, European Inter-University Centre for Human Rights and Democratisation, Cassette tape, Pharmaceutical industry, Medical device

NEW YORK, Oct. 12, 2023 /PRNewswire/ -- REVIV, the global leading IV drip therapy brand, today revealed the results of its customer impact report as the brand heralds its 10th anniversary. With continued global demand in the industry - a market that was valued at $41.7 billion in 2022 and is projected to grow at an accelerated rate - REVIV has taken note of key consumer insights and learnings from over two million IV therapies delivered, and are applying those learnings to continue the growth of their brand. As the brand embarks on the next chapter of its journey, REVIV is introducing its newest offering, REVIV X, an industry-first digital offering that democratises access to IV drip therapy globally and enables the sector to scale at an accelerated pace.

Key Points:

REVIV X allows for unlimited expansion of REVIV-branded services within qualified health and wellness settings.
In addition to REVIV X, REVIV is driving industry transformation across its subsidiary business and new product lines: REVIV clinics, IV PRO and the IV ACADEMY.
This is a new era for REVIV, the global IV drip therapy industry, and for enhanced patient outcomes.
REVIV is trailblazing the nutritional health industry which is why the brand continues to introduce new and exciting product offerings and opportunities.

REVIV, the Global Leader in Personalized and Precision Nutrition, Launches REVIV 2.0, the Next Chapter in Brand History Powered by Over 10 Years of Experience and 2M+ IV Therapies Delivered

Retrieved on:

Thursday, October 12, 2023

NEW YORK, Oct. 12, 2023 /PRNewswire/ -- REVIV, the global leading IV drip therapy brand, today revealed the results of its customer impact report as the brand heralds its 10th anniversary. With continued global demand in the industry - a market that was valued at $41.7 billion in 2022 and is projected to grow at an accelerated rate - REVIV has taken note of key consumer insights and learnings from over two million IV therapies delivered, and are applying those learnings to continue the growth of their brand. As the brand embarks on the next chapter of its journey, REVIV is introducing its newest offering, REVIV X, an industry-first digital offering that democratises access to IV drip therapy globally and enables the sector to scale at an accelerated pace.

Key Points:

REVIV X allows for unlimited expansion of REVIV-branded services within qualified health and wellness settings.
In addition to REVIV X, REVIV is driving industry transformation across its subsidiary business and new product lines: REVIV clinics, IV PRO and the IV ACADEMY.
This is a new era for REVIV, the global IV drip therapy industry, and for enhanced patient outcomes.
REVIV is trailblazing the nutritional health industry which is why the brand continues to introduce new and exciting product offerings and opportunities.

The Ketamine Healing Clinic of Los Angeles and Orange County Introduces an Innovative Approach: Combining Deep TMS and Ketamine Therapy

Retrieved on:

Thursday, October 12, 2023

LOS ANGELES, Oct. 12, 2023 /PRNewswire-PRWeb/ -- Spearheaded by the esteemed Dr. David Mahjoubi, this groundbreaking approach has the potential to revolutionize the field of mental health by offering amplified therapeutic benefits for individuals suffering from depression, anxiety, OCD and smoking addiction. Deep TMS, a non-invasive procedure that uses magnetic fields to stimulate specific areas of the brain, has long been recognized as an effective treatment for various mental health conditions. Ketamine therapy, on the other hand, has gained significant attention in recent years for its rapid and profound effects. By combining these two powerful modalities, Dr. Mahjoubi and his team at the Ketamine Healing Clinic of Los Angeles and Orange County are paving the way for a new era of mental health treatment. This unique combination of deep TMS and ketamine therapy synergistically targets the brain's neural pathways and may provide faster and longer-lasting relief, ultimately improving the quality of life for countless individuals.

Key Points:

The Ketamine Healing Clinic of Los Angeles and Orange County is proud to announce the introduction of an innovative treatment protocol that combines deep transcranial magnetic stimulation (TMS) and ketamine therapy.
By combining these two powerful modalities, Dr. Mahjoubi and his team at the Ketamine Healing Clinic of Los Angeles and Orange County are paving the way for a new era of mental health treatment .
For information on the Ketamine Healing Clinic of Los Angeles and the Ketamine Healing Clinic of Orange County please visit the website at http://www.ketaminehealing.com , or call (424) 278-4241 or (949) 514-8261.
Dr. David Mahjoubi, The Ketamine Healing Clinic of Los Angeles, (424) 278-4241, [email protected] , https://www.ketaminehealing.com/
View original content to download multimedia: https://www.prweb.com/releases/the-ketamine-healing-clinic-of-los-angele...

Bank of South Carolina Corporation Announces Third Quarter Earnings

Retrieved on:

Thursday, October 12, 2023

OTCQX, Pressure, Bank, IV, Federal, Federal Reserve, Cryptocurrency

CHARLESTON, S.C., Oct. 12, 2023 /PRNewswire/ -- The Bank of South Carolina Corporation (OTCQX: BKSC) announced unaudited earnings of $1,263,371, or $0.23 basic and diluted earnings per share, for the quarter ended September 30, 2023 – a decrease of $576,896, or 31.35%, from earnings for the quarter ended September 30, 2022 of $1,840,267, or $0.33 basic and diluted earnings per share.

Key Points:

CHARLESTON, S.C., Oct. 12, 2023 /PRNewswire/ -- The Bank of South Carolina Corporation (OTCQX: BKSC) announced unaudited earnings of $1,263,371, or $0.23 basic and diluted earnings per share, for the quarter ended September 30, 2023 – a decrease of $576,896, or 31.35%, from earnings for the quarter ended September 30, 2022 of $1,840,267, or $0.33 basic and diluted earnings per share.
Unaudited earnings for the nine months ended September 30, 2023 decreased $717,489, or 14.80%, to $4,129,866 compared to $4,847,355 for the nine months ended September 30, 2022.
Eugene H. Walpole, IV, President and Chief Executive Officer, stated, "During the quarter, we experienced sustained pressure on funding costs, as the Federal Reserve continues the march upward in its pursuit to combat inflation.
As a result, net interest spread remains under pressure along with weakening demand for mortgage loans.

NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference

Retrieved on:

Thursday, October 12, 2023

The full presentation may be viewed on the Company's web page Link .

Key Points:

The full presentation may be viewed on the Company's web page Link .
The Company further invites interested parties to subscribe to their email alert service stay up to date on company's progress here: NRX Email Alerts .
The findings of this trial confirm the results reported by Grunebaum and coworkers (Am J Psychiatry 2018;175:327 Link ) and numerous smaller trials.
Preliminary estimates of this regulatory focused work show that this effort is within the company's current budget.

Fem Strong Health Announces Grand Opening For A New Era of Women's Wellness

Retrieved on:

Thursday, October 12, 2023

Health, Tonis, Education, Elective surgery, Multimedia, Menopause, IV, Woman, Patient, Birth control, Nursing

NEW YORK, Oct. 11, 2023 /PRNewswire-PRWeb/ -- "Fem Strong Health is more than just a clinic; it's a wellness sanctuary designed to empower women through personalized, integrated care," says Adam Tonis, CEO. "With a team of renowned specialists in hormonal care, clinical psychology, nutrition, lifestyle intervention, vascular assessment, plastic surgery and more, Fem Strong Health provides a seamless and holistic approach to wellness."

Key Points:

Fem Strong Health, a pioneering multi-specialty clinic dedicated to women's health, is thrilled to announce its grand opening in New York City.
"With a team of renowned specialists in hormonal care, clinical psychology, nutrition, lifestyle intervention, vascular assessment, plastic surgery and more, Fem Strong Health provides a seamless and holistic approach to wellness."
"As we celebrate the grand opening of Fem Strong Health during Menopause Awareness Month, we recognize the importance of comprehensive and compassionate care for women navigating this significant life transition," says Tonis.
"Fem Strong Health invites all to join in celebrating the grand opening and to explore the transformative wellness journey that awaits at the clinic," says Tonis.

B. Braun Launches Introcan Safety® 2 IV Catheter with Multi-Access Blood Control Designed to Protect Clinicians Every Time the Hub is Accessed

Retrieved on:

Wednesday, October 11, 2023

Workload, Risk, APG IV system, IV, Vascular access, Patient, Injury, Medical device, Chief security officer, Marketing

The Introcan Safety 2 IV Catheter is the latest development from B. Braun in a long line of passive needlestick prevention catheters.

Key Points:

The Introcan Safety 2 IV Catheter is the latest development from B. Braun in a long line of passive needlestick prevention catheters.
In addition to automatic needlestick protection, clinicians are protected from blood exposure by a blood control feature every time the hub is accessed1 – reducing the risk of bloodborne pathogen exposure throughout the IV process.
In addition to needlestick injuries, mucocutaneous blood exposure due to blood spillage from the catheter hub is also a concern.
"The newly launched Introcan Safety 2 IV Catheter with Multi-Access Blood Control provides clinicians with another option when choosing the right device for their patients.

Alimentiv and Satisfai Health Announce Commercial Availability of Highly Innovative AI-Powered Scoring Tool for the Assessment of Ulcerative Colitis in Stage I through IV Clinical Trials

Retrieved on:

Tuesday, October 10, 2023

Medicine, Intelligence, AI, IBD, Health, IV, Shoulder, Medical device

Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.

Key Points:

Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.
Certai was developed using a comprehensive global dataset of anonymized IBD colonoscopy videos, with data labeling and clinical oversight from the globally leading experts on the assessment and scoring of IBD within clinical trials.
"Using Certai is like having the world's leading IBD experts on your shoulder," said Dr. Michael Byrne, CEO, Satisfai Health.
We are very excited to bring these advancements in digital analysis into our portfolio," said Jeff Smith, CEO, Alimentiv.

LILEE Systems Announces Acceptance of Collaborative Paper on Train Control 4.0 at Global Conferences

Retrieved on:

Tuesday, October 10, 2023

TC 4.0 was an initiative from the Taiwan Railways Administration (TRA) and was developed by LILEE Systems in partnership with Wistron Corporation, Taiwan Optical Platform and Taiwan Kyosan.

Key Points:

TC 4.0 was an initiative from the Taiwan Railways Administration (TRA) and was developed by LILEE Systems in partnership with Wistron Corporation, Taiwan Optical Platform and Taiwan Kyosan.
Following its successful implementation, execution and verification in 2022, the recognition by the two international conferences strengthens its global relevance in the rail safety space.
Designed to improve TRA's original ATP functionality and prevent train accidents, TC 4.0 is based on advanced communication technologies such as low latency, mission-critical radio and 5G-enabled cellular V2X.
We look forward to the continued collaboration with TRA and technology partners to fulfill our commitment to safety," said LILEE Systems CEO Jia-Ru Li.

Alimentiv and Satisfai Health Announce Commercial Availability of Highly Innovative AI-Powered Scoring Tool for the Assessment of Ulcerative Colitis in Stage I through IV Clinical Trials

Retrieved on:

Tuesday, October 10, 2023

Medicine, Intelligence, AI, IBD, Health, IV, Shoulder, Medical device

Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.

Key Points:

Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.
Certai was developed using a comprehensive global dataset of anonymized IBD colonoscopy videos, with data labeling and clinical oversight from the globally leading experts on the assessment and scoring of IBD within clinical trials.
"Using Certai is like having the world's leading IBD experts on your shoulder," said Dr. Michael Byrne, CEO, Satisfai Health.
We are very excited to bring these advancements in digital analysis into our portfolio," said Jeff Smith, CEO, Alimentiv.